The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward.
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
04
12
2018
revised:
07
12
2018
accepted:
21
12
2018
entrez:
25
3
2019
pubmed:
25
3
2019
medline:
20
8
2019
Statut:
ppublish
Résumé
The Spin-D (Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease) and MiREnDa (Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease) trials taken together provide the reassuring demonstration that up to 25 mg/d spironolactone is reasonably safe, provided maintenance hemodialysis patients are properly monitored and investigators use a per-protocol therapeutic algorithm to manage hyperkalemia. These results should encourage and reassure the investigators of the 2 currently ongoing, large, international, major-outcome clinical trials, both of which are using spironolactone up to 25 mg/d: ACHIEVE (Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease trial; NCT03020303) and ALCHEMIST (ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial; NCT01848639).
Identifiants
pubmed: 30904064
pii: S0085-2538(19)30006-7
doi: 10.1016/j.kint.2018.12.006
pii:
doi:
Substances chimiques
Mineralocorticoid Receptor Antagonists
0
Spironolactone
27O7W4T232
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Pagination
747-749Commentaires et corrections
Type : CommentOn
Type : CommentOn
Informations de copyright
Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.